

Product Data Sheet

IFN-alpha 6/IFNA6 Protein, Human (His-Myc)

Cat. No.: HY-P72244

Synonyms: IFNA6Interferon alpha-6; IFN-alpha-6; Interferon alpha-54; Interferon alpha-K; LeIF K

Species: Source: E. coli

P05013 (S21-E189) Accession:

Gene ID: 3443

Molecular Weight: Approximately 25.1 kDa

PROPERTIES

	uence

SLDCDLPQTH SLGHRRTMML LAQMRRISLF SCLKDRHDFR FPQEEFDGNQ FQKAEAISVL HEVIQQTFNL FSTKDSSVAW DERLLDKLYT ELYQQLNDLE ACVMQEVWVG GTPLMNEDSI LAVRKYFQRI TLYLTEKKYS PCAWEVVRAE IMRSFSSSRN

LQERLRRKE

Appearance

Lyophilized powder.

Formulation

Lyophilized from a 0.2 µm solution of Tris-based buffer, 50% Glycerol.

Endotoxin Level

<1 EU/µg, determined by LAL method.

Reconsititution

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O.

Storage & Stability

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Shipping

Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background

IFN-alpha 6 (IFNA6; IFN-α6), belongs to the alpha/beta interferon (IFN) family, is produced by the macrophages with antiviral activities [1]. Interferon (IFN) is originally identified as a substance 'interfering' with viral replication in vitro. IFN- α/β and related molecules are classified as type I IFNs, as for the other two types of type II IFN (IFN-γ) and type III IFNs (IFN-λ), respectively^[2].

Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase. Interferon alpha (IFNa) shows significant biological activity in various cancers, paticularly haematological malignancies such as hairy cell leukaemia and chronic myelogenous leukaemia^[3].

Type I interferons (IFNs) are produced early in response to viral infection and modulate adaptive immunity. IFN-alpha 6

Page 1 of 2

involves in acute myocarditis and chronic cardiac inflammation inhibition, promotes systemic murine cytomegalovirus (MCMV) infection by reducing MCMV replication^[4].

As for a wildly use of IFN in animal model, the sequence of amino acids in IFNA6 protein of human is very different from mouse (56.61%)

REFERENCES

- [1]. Kumagai Y, et al. Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. Immunity. 2007 Aug;27(2):240-52.
- [2]. Zhang SY, et al. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev. 2008 Dec;226:29-40.
- [3]. Raj NB, et al. Identification of a novel virus-responsive sequence in the promoter of murine interferon-alpha genes. J Biol Chem. 1991 Jun 15;266(17):11360-5.
- [4]. Cull VS, et al. Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis. Immunology. 2002 Jul;106(3):428-37.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com